CNS Pharmaceuticals (NASDAQ:CNSP) Announces Quarterly Earnings Results, Misses Expectations By $0.14 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) issued its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14), FiscalAI reports.

CNS Pharmaceuticals Stock Performance

NASDAQ CNSP traded down $0.34 during mid-day trading on Wednesday, reaching $5.16. 4,287 shares of the stock were exchanged, compared to its average volume of 600,610. CNS Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $10.59. The business’s 50 day moving average is $4.96 and its 200-day moving average is $4.19. The company has a market capitalization of $7.54 million, a P/E ratio of -0.17 and a beta of 3.05.

Insiders Place Their Bets

In related news, Director Faith L. Charles acquired 7,100 shares of CNS Pharmaceuticals stock in a transaction on Monday, May 18th. The stock was bought at an average cost of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the transaction, the director owned 7,100 shares of the company’s stock, valued at approximately $34,009. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.01% of the company’s stock.

Institutional Trading of CNS Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals in the 2nd quarter worth about $335,000. Boothbay Fund Management LLC purchased a new position in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $71,000. Finally, Ikarian Capital LLC purchased a new position in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $241,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.